structural genes (Gag/Pol and Env), Rev is an HIV encoded protein which binds to RRE. This interaction is essential for nucleo-cytoplasmic transport of the RRE containing viral mRNAs and the expression of Gag/Pol and Env proteins. The inventors have produced an attenuated HIV by disabling Rev/RRE, by point mutations, and inserting in its place the novel murine NCTE of the invention. The resultant HIV is attenuated between 50 and 200 fold compared to wild type HIV. Claimed at the novel NCTE, recombinant retroviruses comprising the NCTE and vaccines.

Dated: October 6, 2000.

Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 00–27358 Filed 10–24–00; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Consensus Development Conference on Adjuvant Therapy for Breast Cancer

Notice is hereby given of the National Institutes of Health (NIH) Consensus Development Conference on “Adjuvant Therapy for Breast Cancer,” which will be held November 1–3, 2000, in the NIH’s Natcher Conference Center, 9000 Rockville Pike, Bethesda, Maryland 20892. The conference begins at 8:00 am on November 1 and 2, and at 9:00 am on November 3 and is open to the public.

Each year, more than 180,000 women in the United States are diagnosed with breast cancer, the most common type of non-skin cancer among women in this country. Through continuing research into new treatment methods, women with breast cancer now have more effective treatment options than ever before. Studies have shown that adjuvant therapy—treatment to kill cancer cells that may have begun to spread, or metastasize, from the breast tumor—given in addition to surgery or other primary therapies increases a woman’s chance of long-term survival.

Two types of systemic adjuvant therapy, either alone or in combination, are used for breast cancer. Adjuvant chemotherapy involves a combination of anticancer drugs. Adjuvant hormone therapy deprives cancer cells of the female hormone estrogen, which some breast cancer cells need to grow. In addition to these systemic therapies, radiation therapy is sometimes used as a local adjuvant treatment to help destroy breast cancer cells that have spread to nearby tissues.

The rapid pace of discovery in this area continues to broaden the knowledge base from which informed treatment decisions can be made. The purpose of this conference is to clarify, for clinicians, patients, and the general public, various issues regarding the use of adjuvant therapy for breast cancer. After 1½ days of presentations and audience discussion of the latest adjuvant therapy research, an independent, non-Federal consensus development panel will weigh the scientific evidence and draft a statement that will be presented to the conference audience on the third day. The consensus development panel’s statement will address the following key questions:

- Which factors should be used to select systemic adjuvant therapy?
- For which patients should adjuvant hormonal therapy be recommended?
- For which patients should adjuvant chemotherapy be recommended?
- Which agents should be used and at what dose or schedule?
- For which patients should mastectomy radiotherapy be recommended?

How do side effects and quality-of-life issues factor into individual decision-making about adjuvant therapy?

What are promising new research directions for adjuvant therapy?

On the final day of the conference, the panel’s draft statement will be read in public, at which time members of the public are invited to offer comments on the draft.

The primary sponsors of this meeting are the National Cancer Institute and the NIH Office of Medical Applications of Research. Cosponsors include the National Institute of Nursing Research and the NIH Office of Research on Women’s Health.

This is the 114th Consensus Development Conference held by the NIH in the 23-year history of the Consensus Development Program.

Advance information about the conference and conference registration materials may be obtained from Prospect Associates of Silver Spring, Maryland, by calling (301) 592–3320 or by sending e-mail to breastcancer@prospectassoc.com. Prospect Associates’ address is 10720 Columbia Pike, Suite 500, Silver Spring, Maryland 20901–4437. A conference agenda and registration information is also available on the NIH Consensus Program Web site at http://consensus.nih.gov.


Ruth L. Kirschstein,
Principal Deputy Director, National Institutes of Health.

[FR Doc. 00–27357 Filed 10–24–00; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the National Cancer Institute Board of Scientific Advisors.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(6) and 552b(c)(9)(B), Title 5 U.S.C. The discussions could reveal information of a personal nature where disclosure would constitute a clearly unwarranted invasion of personal privacy and the premature disclosure of discussions related to personnel and confidential administrative information would be likely to significantly frustrate the subsequent implementation of recommendations.

Name of Committee: National Cancer Institute Board of Scientific Advisors.

Date: November 16–17, 2000.
Open: November 16, 8:30 am to 5 pm; November 17, 8:30 am to 2 pm.

Agenda: Report of the Director, NCI; Ongoing and New Business, Status Reports, Budget Presentation, Reports of Special Initiatives, and RFA/RFP Concept Reviews.

Closed: November 16, 5 pm to 6 pm.

Agenda: To review and evaluate personnel and programmatic issues.

Place: National Cancer Institute, 9000 Rockville Pike, Building 31, C Wing, 6 Floor, Conference Room 10, Bethesda, MD 20892.

Contact Person: Paulette S. Gray, Ph.D., Executive Secretary, Deputy Director, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8141, Bethesda, MD 20892.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer